menu
    • menu

    Company profile for PolTREG

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PolTREG S.A. is a biotechnology firm established in 2015, with headquarters and laboratories situated in Gdańsk. Our primary goal is to pioneer efficacious T-regulatory cell (TREG) based therapies for autoimmune diseases, aimed at enhancing the quality of life for patients and their families. At PolTREG, we're advancing four leading projects already in the clinical stage of development, focusing on type 1 diabetes and multipl...
    PolTREG S.A. is a biotechnology firm established in 2015, with headquarters and laboratories situated in Gdańsk. Our primary goal is to pioneer efficacious T-regulatory cell (TREG) based therapies for autoimmune diseases, aimed at enhancing the quality of life for patients and their families. At PolTREG, we're advancing four leading projects already in the clinical stage of development, focusing on type 1 diabetes and multiple sclerosis areas.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PolTREGPoland Flag
    Country
    Country
    Poland
    Address
    Address
    Botaniczna 20, 80-298 Gdańsk
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://poltreg.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/poltreg-s-a/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuthera Secure License for CD6/CTLA-4 CAR-Treg Platform
    Immuthera Secure License for CD6/CTLA-4 CAR-Treg Platform

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-13/immuthera-announces-global-exclusive-license-from-city-of-hope-for-first-in-class-cd6ctla-4-car-treg-platform-for-autoimmune-and-inflammatory-disease

    PHARMIWEB
    12 Jan 2026
    Share Share
    Dr. Adrian Bot Joins Immuthera To Drive Commercialization
    Dr. Adrian Bot Joins Immuthera To Drive Commercialization

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183600/0/en/Dr-Adrian-Bot-joins-Immuthera-to-support-the-company-with-his-unique-experience-in-commercialization-of-groundbreaking-cell-therapies.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    PolTREG Injects First Patient in Phase Ii Trial
    PolTREG Injects First Patient in Phase Ii Trial

    04 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/04/3126793/0/en/PolTREG-Doses-First-Patient-in-Phase-II-Trial-for-Pre-Symptomatic-Type-1-Diabetes-with-PTG-007.html

    GLOBENEWSWIRE
    04 Aug 2025
    Share Share
    PolTREG, Immuthera Get Positive FDA Nod for Pre T1D Trial
    PolTREG, Immuthera Get Positive FDA Nod for Pre T1D Trial

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3125327/0/en/PolTREG-and-U-S-Subsidiary-Immuthera-Secure-Positive-FDA-Opinion-Paving-the-Way-for-a-Registrational-Pre-Symptomatic-Type-1-Diabetes-Trial.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    Immuthera Appoints Top Experts to Scientific Advisory Board
    Immuthera Appoints Top Experts to Scientific Advisory Board

    04 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/04/3110318/0/en/Immuthera-s-Scientific-Advisory-Board-World-Leading-Expertise-Driving-Next-Generation-Diabetes-and-Immunotherapy-Solutions.html

    GLOBENEWSWIRE
    04 Jul 2025
    Share Share
    PolTREG Forms U.S. Unit Immuthera for Global Expansion
    PolTREG Forms U.S. Unit Immuthera for Global Expansion

    13 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/13/3099162/0/en/PolTREG-Establishes-U-S-Subsidiary-Immuthera-to-Advance-International-Development-Strategy.html

    GLOBENEWSWIRE
    13 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search